Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Viewpoint - The presentation at the 2026 JPMorgan Healthcare Conference highlights the commitment of Perceptive Therapeutics to patient-centered care, emphasizing the impact of their treatments on patients with serious conditions like neuroendocrine cancer [2][3]. Company Overview - Perceptive Therapeutics is focused on developing innovative treatments for patients with complex medical conditions, showcasing their dedication to improving patient outcomes [2]. - The company presented a case study of an elderly woman with neuroendocrine cancer who experienced tumor progression and was treated with their drug, VMT-alpha-NET, resulting in a significant reduction in tumor size after the first dose [3]. Industry Context - The healthcare industry is increasingly prioritizing patient outcomes and personalized medicine, as demonstrated by the case presented at the conference [2][3].